Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study

Authors:

Abstract
Aims Type 2 diabetes mellitus (T2DM) is a public health threat. Men with T2DM often exhibit hypogonadism. We investigated whether testosterone therapy (TTh) in men with hypogonadism and T2DM improves glycemic control, insulin sensitivity and results in remission of T2DM. Material and Methods 356 men who had total testosterone (T) ≤12.1 nmol/L (350 ng/dL) and symptoms of hypogonadism were included in the study and observed for 11 years. All patients received standard diabetes treatment. 178 men additionally received parenteral T undecanoate 1000 mg every 12 weeks following an initial 6‐week interval. 178 hypogonadal men who opted against TTh served as control group. Results Men with hypogonadism and T2DM treated with T had significant progressive and sustained reductions in fasting glucose, HbA1c and fasting insulin over the treatment period. In the control group, fasting glucose, HbA1c and fasting insulin increased. 34.3% of men treated with T achieved remission of their diabetes and 46.6% of patients achieved normal glucose regulation. 83.1% of the T‐treated group reached HbA1c target of 6.5%, 90% achieved HbA1c target of 7.0%. In contrast, no remission of diabetes or reduction in glucose or HbA1c levels were noted in the control group. There were fewer deaths, myocardial infarctions, strokes, and diabetic complications in the T‐treated group. Conclusions Long‐term TTh in men with T2DM and hypogonadism improves glycemic control and insulin resistance. Remission of diabetes occurred in one third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.
Funding Information
  • Bayer

This publication has 47 references indexed in Scilit: